Laboratory of Genetics, Division of Oncology, CIMA, University of Navarra, Pamplona, Spain.
Oncogene. 2013 Apr 18;32(16):2069-78. doi: 10.1038/onc.2012.222. Epub 2012 Jun 11.
The EVI1 gene (3q26) codes for a transcription factor with important roles in normal hematopoiesis and leukemogenesis. High expression of EVI1 is a negative prognostic indicator of survival in acute myeloid leukemia (AML) irrespective of the presence of 3q26 rearrangements. However, the only known mechanisms that lead to EVI1 overexpression are 3q aberrations, and the MLL-ENL oncoprotein, which activates the transcription of EVI1 in hematopoietic stem cells. Our aim was to characterize the functional promoter region of EVI1, and to identify transcription factors involved in the regulation of this gene. Generation of seven truncated constructs and luciferase reporter assays allowed us to determine a 318-bp region as the minimal promoter region of EVI1. Site-directed mutagenesis and chromatin immunoprecipitation (ChIP) assays identified RUNX1 and ELK1 as putative transcription factors of EVI1. Furthermore, knockdown of RUNX1 and ELK1 led to EVI1 downregulation, and their overexpression to upregulation of EVI1. Interestingly, in a series of patient samples with AML at diagnosis, we found a significant positive correlation between EVI1 and RUNX1 at protein level. Moreover, we identified one of the roles of RUNX1 in the activation of EVI1 during megakaryocytic differentiation. EVI1 knockdown significantly inhibited the expression of megakaryocytic markers after treating K562 cells with TPA, as happens when knocking down RUNX1. In conclusion, we define the minimal promoter region of EVI1 and demonstrate that RUNX1 and ELK1, two proteins with essential functions in hematopoiesis, regulate EVI1 in AML. Furthermore, our results show that one of the mechanisms by which RUNX1 regulates the transcription of EVI1 is by acetylation of the histone H3 on its promoter region. This study opens new directions to further understand the mechanisms of EVI1 overexpressing leukemias.
EVI1 基因(3q26)编码一种转录因子,在正常造血和白血病发生中具有重要作用。EVI1 的高表达是急性髓细胞白血病(AML)患者生存的不良预后指标,与 3q26 重排的存在无关。然而,导致 EVI1 过表达的唯一已知机制是 3q 异常和 MLL-ENL 癌蛋白,它们激活造血干细胞中 EVI1 的转录。我们的目的是研究 EVI1 的功能启动子区域,并鉴定参与该基因调控的转录因子。通过生成七个截断构建体和荧光素酶报告基因测定,我们确定了 318bp 区域作为 EVI1 的最小启动子区域。定点突变和染色质免疫沉淀(ChIP)测定鉴定出 RUNX1 和 ELK1 是 EVI1 的潜在转录因子。此外,RUNX1 和 ELK1 的敲低导致 EVI1 的下调,而过表达则导致 EVI1 的上调。有趣的是,在一系列初诊 AML 患者样本中,我们发现 EVI1 和 RUNX1 在蛋白水平上存在显著的正相关。此外,我们确定了 RUNX1 在巨核细胞分化过程中激活 EVI1 的作用之一。EVI1 敲低显著抑制了 K562 细胞在用 TPA 处理后表达巨核细胞标志物,就像敲低 RUNX1 时一样。总之,我们定义了 EVI1 的最小启动子区域,并证明 RUNX1 和 ELK1 这两种在造血中具有重要功能的蛋白质在 AML 中调节 EVI1。此外,我们的结果表明,RUNX1 调节 EVI1 转录的机制之一是通过其启动子区域上组蛋白 H3 的乙酰化。这项研究为进一步了解 EVI1 过表达白血病的机制开辟了新的方向。